FDA approves Impax generic of Merck's cholesterol drug Vytorin

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Merck & Co's cholesterol-reducing drug Vytorin, the first cheap competitor for a drug that in 2016 generated more than $1 billion in sales.